PEN (Penumbra) Stock Based Compensation: $60 Mil (TTM As of Mar. 2026)


PEN Penumbra Inc PEN
89 GF Score
Price $318.31
GF Value $332.27
Valuation Fairly Valued
! 1 Warning Sign
View Full Analysis

What is Penumbra Stock Based Compensation?

Penumbra PEN +0.03% 89 Stock Based Compensation is $60 Mil as of Mar. 2026. GuruFocus rates PEN with a GF Score™ of 89/100 and a GF Value™ of $332.27 (Fairly Valued). The stock has 1 warning sign investors should review.

Penumbra's Stock Based Compensation for the three months ended in Mar. 2026 was $15 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2026 was $60 Mil.

Penumbra Stock Based Compensation Related Terms

Penumbra Stock Based Compensation Historical Data

* Premium members only.

The historical data trend for Penumbra's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Penumbra Stock Based Compensation Chart

Penumbra Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Stock Based Compensation
Get a 7-Day Free Trial Premium Member Only Premium Member Only 65.76 37.38 50.52 46.16 59.21

Penumbra Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 13.79 14.23 15.93 15.26 14.65
PEN
89GF Score
Penumbra Inc PEN
Stock Based Compensation is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Penumbra Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $60 Mil.

What does a Stock Based Compensation of $60 Mil mean?
Penumbra (PEN) has a Stock Based Compensation of $60 Mil as of Mar. 2026. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Penumbra and its competitors.
Is Penumbra's Stock Based Compensation too high?
Penumbra's current Stock Based Compensation is $60 Mil. Overall, Penumbra has a GF Score™ of 89/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Penumbra's Stock Based Compensation compare to GMED and PODD?
Penumbra's Stock Based Compensation of $60 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Stock Based Compensation for a Medical Devices & Instruments company?
A good Stock Based Compensation depends on the Medical Devices & Instruments industry context. However, Stock Based Compensation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Stock Based Compensation mean?
A high Stock Based Compensation can signal that a stock is expensive relative to its fundamentals. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Penumbra and its competitors. Penumbra's current Stock Based Compensation is $60 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Penumbra stock overvalued right now?
Based on GuruFocus' analysis, Penumbra (PEN) is currently considered Fairly Valued. The stock's GF Value™ is $332.27, compared to a current price of $318.31 — trading 4.2% below its estimated fair value. The current Stock Based Compensation is $60 Mil. Penumbra's overall GF Score™ is 89/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Stock Based Compensation calculated?
Stock Based Compensation is calculated from a company's financial statements. For Penumbra (PEN), the current Stock Based Compensation is $60 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Penumbra (PEN) Overvalued in 2026?

Based on GuruFocus' analysis, Penumbra stock appears to be undervalued. The current stock price of $318.31 is trading 4.2% below its estimated GF Value™ of $332.27. GuruFocus considers Penumbra to be Fairly Valued.

Key valuation signals for PEN:

  • Stock Based Compensation: $60 Mil
  • GF Value™: $332.27 vs. price of $318.31 (4.2% below fair value)
  • GF Score™: 89/100 with 1 warning sign

No single metric tells the full story. See the PEN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Penumbra Business Description

Other Exchanges 0P8:Germany
Address 1310 Harbor Bay Parkway, One Penumbra Place, Alameda, CA, USA, 94502
Penumbra Inc is a thrombectomy company focused on developing technologies for challenging medical conditions such as ischemic stroke, venous thromboembolism (including pulmonary embolism), and acute limb ischemia. Its portfolio includes Computer-Assisted Vacuum Thrombectomy (CAVT), which is designed to remove blood clots throughout the body. The company offers products such as the Artemis Neuro Evacuation Device (used for surgical removal of fluid and tissue from the ventricles and cerebrum), Indigo System, Penumbra System Reperfusion Catheter, LANTERN Delivery Microcatheter, Penumbra Smart Coil, and ACE Reperfusion Catheters, among others. The company generates maximum revenue from the sale of its products in the United States, followed by international markets.
89GF Score

Get the complete analysis for PEN

Stock Based Compensation is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$318.31
Price
$332.27
GF Value